A Dose-Escalation Phase II Clinical Trial of Infusional Mitomycin C for 7 Days in Patients with Advanced Measurable Colorectal Cancer Refractory or Resistant to 5-Fluorouracil

References

• Erlichman C, Fine S, Wong A, et al. A randomized trial of fluo-rouracil with folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469–475
   PubMed Web of Science ®Google Scholar
• Petrelli N, Douglass H, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419–1426
   PubMed Web of Science ®Google Scholar
• Poon M, O'Connell M, Moertel M, et al. Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407–1418
   PubMed Web of Science ®Google Scholar
• Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized mal of 5-fluorouracil versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559–1565
   PubMed Web of Science ®Google Scholar
• Valone F, Friedman M, Wittlinger P, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: a randomized trial of the Northem California Oncology Group. J Clin Oncol 1989; 7: 1427–1436
   PubMed Web of Science ®Google Scholar
• Poon M, O'Connell M, Wieand H, et al. Biochemical modulation of Auorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967–1972
   PubMed Web of Science ®Google Scholar
• Lokich J, Bothe A, Fine N, et al. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565–2568
   PubMed Web of Science ®Google Scholar
• Hansen R, Quebbeman E, Ausman R, et al. Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. J Surg Oncol 1989; 40: 177–181
   PubMed Web of Science ®Google Scholar
• Wade J, Herbst S, Greenberg A. Prolonged venous infusion of 5-fluorouracil for metastatic colon cancer-a follow-up report [abstract]. Proc Am Soc Clin Oncol 1988; 7: 94
   Google Scholar
• Belt R, Davidner M, Myron M, et al. Continuous low-dose 5-fluorouracil for adenocarcinoma: confirmation of activity [abstract]. Proc Am Soc Clin Oncol 1985; 4: 90
   Google Scholar
• Lokich J, Ahlgren J, Gullo J, et al. A prospective randomized coniparison of infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–432
   PubMed Web of Science ®Google Scholar
• Lokich J, Ahlgren J, Gullo J, et al. A prospective randomized study of continuous infusion 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. Cancer 1991; 67: 14–19
   PubMed Web of Science ®Google Scholar
• Leichman C, Fleming R, Muggia F, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303–1311
   PubMed Web of Science ®Google Scholar
• Hansen R, Ryan L, Anderson T, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996; 88: 668–674
   PubMed Web of Science ®Google Scholar
• Rinaldi D, Bums H, Dorr F, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13: 2842–2850
   PubMed Web of Science ®Google Scholar
• Cunningham D, Zalcberg J, Smith I, et al. “Tomudex” (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumors. Ann Oncol 1996; 7: 179–182
   PubMed Web of Science ®Google Scholar
• Clarke S, Hanwell J, deBoer M, et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996; 14: 1495–1503
   PubMed Web of Science ®Google Scholar
• Jackman A, Calvert A. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann Oncol 1995; 6: 871–881
   PubMed Web of Science ®Google Scholar
• Baccanari D, Davis S, Knick V, et al. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc Natl Acad Sci USA 1993; 90: 11064–11068
   PubMed Web of Science ®Google Scholar
• Spector T, Hanington J, Porter D. 5-Ethynyluracil (776C85): in-activation of dhydropyrimidine dehydrogenase in vivo. Biochem Phmacol 1993; 46: 2243–2248
   PubMed Web of Science ®Google Scholar
• Rowinsky E, Baker S, Spector T, et al. Early clinical evaluation of the dihydropyrimidine dehydrogenase inhibitor 776C85 and oral 5-fluorouracil [abstract]. Cancer Invest 1996; 14(Suppl. 1)39
   Google Scholar
• Bums H, Von Hoff D, Ratain M, et al. Initial phase I trial of dihydropyrimidine dehydrogenase inactivator 5-ethynyluracil (776C85) plus 5-fluorouracil (5-FU) [abstract]. Ann Oncol 1996; 7(Snppl. 1)29
   Google Scholar
• Rothenberg M, Eckardt J, Juhn J, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: 1128–1135
   PubMed Web of Science ®Google Scholar
• Shimada Y, Yooshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993; 11: 909–913
   PubMed Web of Science ®Google Scholar
• Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996; 23(Snppl. 3)34–41
   PubMedGoogle Scholar
• Doll D, Weiss R, Issell B. Mitomycin: ten years after approval for marketing. J Clin Oncol 1985; 3: 276–286
   PubMed Web of Science ®Google Scholar
• Livingstone R, Carter S. Single Agents in Cancer Chemotherapy. IFI/Plenum Press, New York 1970
   Google Scholar
• Lokich J, Pem J, Fine N, et al. Mitomycin C: phase I study of a constant infusion ambulatory treatment schedule. Am J Clin Oncol 1982; 5: 443–447
   PubMed Web of Science ®Google Scholar
• Anderson N, Lokich J, Moore C, et al. Infusional mitomycin C (MMC) for treatment of measurable colorectal carcinoma (CRC) resistant to 5-fluorouracil (EW) [abstract]. Proc Am SOC Clin Oncol 1992; 11: 191
   Google Scholar
• Benvenuto J, Anderson R, Kerkof K, et al. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981; 38: 1914–1918
   PubMedGoogle Scholar
• Bern M, Lokich J, Wallach S, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423–428
   PubMed Web of Science ®Google Scholar
• Poplin E, LoRusson P, Lokich J, et al. Randomized clinical trial of mitomycin C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994; 33: 415–419
   PubMed Web of Science ®Google Scholar
• Ardalan B, Restrepo A, Deng Z, et al. Phase I-II trial of high dose 24-hour infusion of fluorodeoxyuridine (FUdR) in patients with colorectal cancers (previously failed 5-fluorouracil) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 202
   Google Scholar